These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19369120)

  • 41. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mycobacterium haemophilum infection after alemtuzumab treatment.
    Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K
    Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
    Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
    Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
    Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
    Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
    Thachil J; Jadhav V; Gautam M; McKew S; Arumainathan A; Collins D; Smyth C; Harper J; Pettitt A
    Br J Haematol; 2007 Aug; 138(4):559-60. PubMed ID: 17587337
    [No Abstract]   [Full Text] [Related]  

  • 46. [A new therapeutic alternative in chronic B-lymphocytic leukemia].
    Portal E
    Rev Infirm; 2002 Dec; (86):38-40. PubMed ID: 12630232
    [No Abstract]   [Full Text] [Related]  

  • 47. Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells.
    Liebner S; Kniesel U; Kalbacher H; Wolburg H
    Eur J Cell Biol; 2000 Oct; 79(10):707-17. PubMed ID: 11089919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
    Cooles FA; Jackson GH; Menon G; Isaacs JD
    Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
    [No Abstract]   [Full Text] [Related]  

  • 49. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
    Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL
    J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
    Isaacs JD; Hazleman BL; Chakravarty K; Grant JW; Hale G; Waldmann H
    J Rheumatol; 1996 Jun; 23(6):1103-6. PubMed ID: 8782148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urine-based detection of intestinal tight junction loss.
    Thuijls G; Derikx JP; de Haan JJ; Grootjans J; de Bruïne A; Masclee AA; Heineman E; Buurman WA
    J Clin Gastroenterol; 2010 Jan; 44(1):e14-9. PubMed ID: 19525861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
    Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
    Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
    [No Abstract]   [Full Text] [Related]  

  • 53. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ; Lick SD
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
    Moreau T; Coles A; Wing M; Isaacs J; Hale G; Waldmann H; Compston A
    Brain; 1996 Feb; 119 ( Pt 1)():225-37. PubMed ID: 8624684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. More on anti-glomerular basement membrane disease after alemtuzumab.
    Shin JI; Lee JS
    N Engl J Med; 2008 Dec; 359(23):2501-2; author reply 2502. PubMed ID: 19052136
    [No Abstract]   [Full Text] [Related]  

  • 56. Clostridium perfringens enterotoxin and intestinal tight junctions.
    McClane BA
    Trends Microbiol; 2000 Apr; 8(4):145-6. PubMed ID: 10754565
    [No Abstract]   [Full Text] [Related]  

  • 57. Claudin expression modulations reflect an injury response in the murine epidermis.
    Arabzadeh A; Troy TC; Turksen K
    J Invest Dermatol; 2008 Jan; 128(1):237-40. PubMed ID: 17625592
    [No Abstract]   [Full Text] [Related]  

  • 58. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation.
    van der Velden VH
    Haematologica; 2006 Mar; 91(3):291A. PubMed ID: 16531248
    [No Abstract]   [Full Text] [Related]  

  • 59. Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood.
    Hale G
    Transfus Sci; 1999 Dec; 21(3):181-4. PubMed ID: 10848438
    [No Abstract]   [Full Text] [Related]  

  • 60. Lymphocyte depletion for kidney transplantation: back to the past?
    Cravedi P; Mannon RB; Remuzzi G
    Nat Clin Pract Nephrol; 2008 Oct; 4(10):534-5. PubMed ID: 18725917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.